AGC Biologics and BioConnection Partner to Offer new End-to-End Biopharmaceutical Drug Substance and Drug Product Development and Manufacturing Offering
May 22, 2024 08:16 ET
|
BioConnection
AGC Biologics and BioConnection Partner to Offer new End-to-End Biopharmaceutical Drug Substance and Drug Product Development and Manufacturing Offering Strategic partnership provides a...
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
May 22, 2024 08:00 ET
|
Assembly Biosciences, Inc.
-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio’s long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at...
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
May 22, 2024 07:00 ET
|
Entero Therapeutics, Inc.
BOCA RATON, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (Nasdaq: ENTO) (“Entero” or the “Company”), a late clinical-stage...
PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon
May 21, 2024 12:35 ET
|
PRISM MarketView
PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon
Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events
May 21, 2024 09:35 ET
|
Intrommune Therapeutics
Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events
Multiomics Market Size, Share & Trends Analysis Report 2024-2030: Decreasing Costs of Omics Technologies, Public Players are Expected to Drive Expansion
May 21, 2024 09:30 ET
|
Research and Markets
Dublin, May 21, 2024 (GLOBE NEWSWIRE) -- The "Multiomics Market Size, Share & Trends Analysis Report By Product & Service (Instruments, Consumables), By Type (Single-cell, Bulk), By...
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
May 21, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
May 20, 2024 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new...
Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June
May 20, 2024 07:03 ET
|
Wugen
Wugen Announces RMAT and PRIME Designations for WU-CART-007 and Plans to Present Positive Phase 2 Study Findings at EHA 2024
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
May 17, 2024 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the Company will host the muscle biology-focused Contemporary Landscapes in...